Here’s a startling revelation: your weight might significantly influence the success of cutting-edge cancer treatments. A recent study has uncovered a surprising U-shaped relationship between body mass index (BMI) and the outcomes of CAR T-cell therapy in multiple myeloma (MM) patients, with those in the overweight category faring worse than both normal-weight and obese individuals. But here's where it gets controversial—could being overweight actually undermine the effectiveness of this groundbreaking therapy? Let’s dive into the details.
Published in Blood Immunology & Cellular Therapy, this retrospective analysis examined 134 MM patients treated with anti-BCMA CAR T-cell therapy at Massachusetts General Hospital between 2016 and 2023. Patients were categorized by BMI: normal (<25 kg/m²), overweight (25–29.9 kg/m²), and obese (≥30 kg/m²). The findings? Overweight patients showed significantly poorer 12-month progression-free survival (PFS), overall survival (OS), and complete response rates compared to their normal-weight and obese counterparts. For instance, the 12-month PFS rates were 28.8% for overweight patients, 51.9% for normal-weight patients, and 62.6% for obese patients (P < .001).
And this is the part most people miss: the study suggests that obesity might paradoxically enhance immunotherapy sensitivity, while the overweight state appears to lack the protective benefits of either normal weight or obesity. The authors term this phenomenon an ‘immunometabolic valley,’ where overweight patients sit at the most disadvantageous point. But why does this happen? The authors hypothesize that normal-weight patients may have more favorable tumor biology, while obesity could confer metabolic advantages that improve CAR T-cell therapy efficacy—a counterintuitive finding that challenges conventional wisdom.
However, it’s important to note that BMI is a crude measure, lumping together adiposity and lean mass, which may not fully capture an individual’s metabolic health. This limitation underscores the need for more comprehensive body composition analyses in future studies. As a single-center observational study, it’s also subject to selection bias, meaning these findings should be interpreted with caution.
So, what does this mean for the future of CAR T-cell therapy? The authors call for mechanistic studies to identify modifiable biological factors that could optimize treatment outcomes for MM patients across different BMI categories. But here’s the thought-provoking question: Should BMI be considered a critical factor in patient selection or treatment planning for CAR T-cell therapy? Could this research lead to personalized treatment strategies that account for metabolic health? Weigh in below—do you think BMI should play a bigger role in cancer treatment decisions? Your perspective could spark a much-needed conversation.
